Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

Fig. 5

anti-CDCP1 therapy enhances cisplatin tumour growth inhibition in a patient-derived NSCLC xenograft model. αCDCP1-Ab3 delivered at 30 mg/kg causes enhanced tumour growth inhibition of a stage IV metastatic NSCLC tumour when co-administered with cisplatin, but has no effect as a single agent. a Tumour growth curves for patient-derived NSCLC xenografts, treated with anti-CDCP1, cisplatin or a combination. Data shown are averages ± SD for 9 mice per treatment arm. b Survival curves for reaching 2000 mm3 tumour volumes. The anti-CDCP1 + cisplatin combination significantly extended the time to reach 2000 mm3 tumours over cisplatin alone, with median survival of 33.5 v. 25.0 days, p = 0.011 (Mantel-Cox test)

Back to article page